Vontobel Holding Ltd. Increases Stock Position in IQVIA Holdings Inc. $IQV

Vontobel Holding Ltd. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 909.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 550,430 shares of the medical research company’s stock after buying an additional 495,884 shares during the quarter. Vontobel Holding Ltd.’s holdings in IQVIA were worth $104,549,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Canada Pension Plan Investment Board grew its position in IQVIA by 7.3% in the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after acquiring an additional 312,807 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of IQVIA by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership bought a new position in shares of IQVIA during the 2nd quarter valued at about $515,772,000. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 22.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after buying an additional 581,157 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Up 0.3%

NYSE IQV opened at $225.15 on Wednesday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $234.29. The stock has a market capitalization of $38.34 billion, a PE ratio of 30.88, a PEG ratio of 2.52 and a beta of 1.37. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The business’s 50-day moving average is $219.88 and its 200 day moving average is $193.90.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter last year, the business posted $2.84 EPS. The business’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. UBS Group upped their price target on shares of IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Finally, HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and increased their target price for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $243.19.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.